Giant cell tumours of bone treated with denosumab: histological, immunohistochemical and <i>H3F3A</i> mutation analyses

Abstract

Denosumab therapy effectively decreases the number of osteoclastic cells in GCTBs. However, the neoplastic cells with H3F3A mutation survive denosumab treatment and undergo dramatic histological changes in response to this agent.